95 related articles for article (PubMed ID: 9361369)
1. Efficacy of pentasaccharide in a dog model of hemodialysis.
Hoppensteadt DA; Jeske WP; Walenga JM; Fu K; Yang LH; Ing T; Herbert JM; Fareed J
Thromb Res; 1997 Oct; 88(2):159-70. PubMed ID: 9361369
[TBL] [Abstract][Full Text] [Related]
2. Laboratory monitoring of pentasaccharide in a dog model of hemodialysis.
Hoppensteadt DA; Jeske WP; Walenga JM; Fu K; Yang LH; Ing TS; Herbert JM; Fareed J
Thromb Res; 1999 Oct; 96(2):115-24. PubMed ID: 10574589
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
[TBL] [Abstract][Full Text] [Related]
4. Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity.
Walenga JM; Petitou M; Samama M; Fareed J; Choay J
Thromb Res; 1988 Dec; 52(6):553-63. PubMed ID: 3232125
[TBL] [Abstract][Full Text] [Related]
5. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
Walenga JM; Bara L; Petitou M; Samama M; Fareed J; Choay J
Thromb Res; 1988 Jul; 51(1):23-33. PubMed ID: 3166242
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.
Pislaru SV; Pislaru C; Zhu X; Arnout J; Stassen T; Vanhove P; Herbert JM; Meuleman DG; Van de Werf F
Thromb Haemost; 1998 Jun; 79(6):1130-5. PubMed ID: 9657437
[TBL] [Abstract][Full Text] [Related]
8. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of optimal dosage of heparin in hemodialysis patients by thromboelastograph].
Yang ST; Wu H; Gao XY; Hu J; Xiao YF
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 45(4):625-9. PubMed ID: 23939176
[TBL] [Abstract][Full Text] [Related]
10. [Antithrombotic effects of low molecular weight heparin (FR-860) in rabbits].
Hamano S; Komatsu H; Ikeda S; Sakuragawa N
Nihon Yakurigaku Zasshi; 1989 Oct; 94(4):237-42. PubMed ID: 2613104
[TBL] [Abstract][Full Text] [Related]
11. Use of single dose low-molecular-weight heparin in long hemodialysis.
Lai KN; Ho K; Li M; Szeto CC
Int J Artif Organs; 1998 Apr; 21(4):196-200. PubMed ID: 9649059
[TBL] [Abstract][Full Text] [Related]
12. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
Lord H; Jean N; Dumont M; Kassis J; Leblanc M
Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404
[TBL] [Abstract][Full Text] [Related]
13. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
Thomas DP; Merton RE; Gray E; Barrowcliffe TW
Thromb Haemost; 1989 Apr; 61(2):204-7. PubMed ID: 2546282
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of low molecular weight heparin on the hemodialysis model in dogs.
Hamano S; Komatsu H; Ikeda S; Takahashi K; Oguma Y; Sakuragawa N
Thromb Res; 1989 Aug; 55(4):439-49. PubMed ID: 2554525
[TBL] [Abstract][Full Text] [Related]
16. Glycosaminoglycan backbone is not required for the modulation of hemostasis: effect of different heparin derivatives and non-glycosaminoglycan analogs.
Bouças RI; Jarrouge-Bouças TR; Lima MA; Trindade ES; Moraes FA; Cavalheiro RP; Tersariol IL; Hoppenstead D; Fareed J; Nader HB
Matrix Biol; 2012 Jun; 31(5):308-16. PubMed ID: 22504459
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of anti-Xa activity during combined defibrotide-heparin administration in hemodialysis.
Buccianti G; Valenti G; Lorenz M; Cresseri D; Strada E; Nazzari M
Int J Artif Organs; 1990 Jul; 13(7):416-20. PubMed ID: 2401580
[TBL] [Abstract][Full Text] [Related]
18. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study.
Coussement PK; Bassand JP; Convens C; Vrolix M; Boland J; Grollier G; Michels R; Vahanian A; Vanderheyden M; Rupprecht HJ; Van de Werf F;
Eur Heart J; 2001 Sep; 22(18):1716-24. PubMed ID: 11511121
[TBL] [Abstract][Full Text] [Related]
19. [Appropriate dosage of unfraction heparin and low molecular weight heparin in hemodialysis patients].
Xiao Q; Sun XF; Zhang D; Ma ZF; Wu MG; Wang H; Chen XM
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):187-91. PubMed ID: 20356555
[TBL] [Abstract][Full Text] [Related]
20. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
